53 results about "Cefepime" patented technology

The invention relates to an improved therapy for treating resistant bacterial infections caused by extended-spectrum β-lactamase (ESBLs)-producing strains in a warm-blooded animal, adjuvant step down therapy, and pharmaceutical compositions for such therapies. The invention also relates to a method for inhibiting bacterial resistance in ESBLs-producing strains so as to have better control over the therapy; achieve reduced hospital stay and adjuvant step down therapy so as to avoid recrudescence. In particular, the therapy includes antibacterial combination of cefepime with sulbactam via parenteral route, followed by oral third generation cephalosporin with a suitable β lactamase inhibitor.

The invention belongs to the field of medical intermediate and particularly relates to a synthesis method of cefepime hydrochloride. The method comprises the following steps: adding (6R,7R)-7-amino-3-[(1-methyl-1-pyrrolidine)methyl]cef-3-ene-4-carboxylic acid hydrochloride and AE active ester in a mixed solvent of water and a water-soluble organic solvent; adjusting the pH value to 5.5-7.5, and performing an acylation reaction while keeping the temperature; extracting after the reaction, and recycling the organic phase through reduced pressure distillation; and adjusting the pH value of the water phase with hydrochloric acid, and crystallizing to prepare cefepime hydrochloride. The reaction is milder and adopts an acidic or nearly neutral environment, the influence of the reaction on cefepime is lower, the reaction is easier to control, the degradation probability and ring opening probability can be reduced, the purity of the finished product can be increased, the yield of cefepime can be increased, the quality of cefepime can be increased and the purity is above 99.5% through high performance liquid chromatography (HPLC) detection.

Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of the infective organism. Methods of treating a cefepime resistant bacterial infection in a patient are also provided.

Process for producing Cefepime, Cefpirome and Cefquinome, whereby a cephalosporin containing a quaternary ammonium group is reacted with thiourea to provide the aforesaid cephalosporins.

The invention provides a synthesis method of cefepime hydrochloride. The synthesis method comprises the following steps: taking GCLE (7-phenylacetamide-3-chloromethyl-3-cepham-4-carboxylic acid p-methyl-oxybenzyl ester) as a raw material; cutting a 4-site protecting group (p-methoxybenzyl) and enabling the 4-site protecting group to react with N-methylpyrrolidine (NMP); then cutting a 7-site protecting group through an enzyme method to obtain an immediate 7-amino-3-(1-methylpyrrolidine)methyl)-3-cepham-4-carboxylic acid hydrochloride (7-ACP); taking cheap and available methoxyiminoacetic acid mercaptobenzothiazole active ester (AE-active ester) and the 7-ACP to be subjected to 7-site acylation reaction, so as to finally prepare the cefepime hydrochloride. A route provided by the invention can be used for obtaining the high-yield and high-quality cefepime hydrochloride without a delta2 isomer. The synthesis method provided by the invention has the advantages of simple process, no harsh reaction conditions and the like and is very suitable for industrial production.

The present invention relates to 7beta-alkylamido-3-(1-methyl-1-pyrrolidyl onium) methyl-3-cephalo olefine-4-carboxylate and its preparation process and the synthesizing process of cephalo pyroxime hydrochloride with the said intermediate. The present invention has mild reaction condition, no need of expensive reagent and benzyl penicillin acylase, low cost, high product purity, and simple and practical reaction path.

The invention provides a method for preparing cefepime dihydrochloride. The method employs the raw materials of 7-ACA, HMDS, TMSI, NMP and CH3OH, and a catalyst is hydrochloric acid having 98% of concentration. According to the invention, the method employs a one kettle way, a cefepime dihydrochloride crude product is prepared, then the cefepime dihydrochloride crude product is purified, and finally cefepime dihydrochloride is obtained. The purity of the cefepime dihydrochloride is 97%, yield can reach 31.3%, compared with the current synthesis technology, the yield is increased by 3.3-10% (by metering with 7-ACA), and the purity is increased by 4%. The preparation method has the advantages that the industrial production requirements of short reaction period, easily available raw materials and low cost can be satisfied, and has industrial application.

The present invention provides a method for synthesizing cefepime intermidiate in mixed solvent. The method is : using 7-ACA as material, generating 3-iodo intermediate and reacting with N-methyl pyrrolidine in mixed solution of methylene chloride and N,N-dimethyl formamide etc, high quality, high yield, delta2 isomer-free cefepime intermidiate 7-amido-3-[(1-methyldihydropyrrole)methyl]-3-cepha-4- carboxylate hydrochloride (7-ACP) 7-ACP yield amounts to 80% (mol yield) and is higher than existing technology. Tone grade of 7-ACP is less than 3,and purity is larger than 99.5%.

The invention relates to a preparation or purification method of cefepime dihydrochloride monohydrate. The invention is characterized in that acetone, ethanol or the mixed solution of acetone and ethanol at the random portion is added into the methanol solution containing cefepime dihydrochloride and then cefepime dihydrochloride monohydrate crystal is precipitated. The method can effectively avoid the formation of cefepime dihydrochloride dihydrate.

The invention discloses a method for enriching staphylococcus aureus by magnetic beads, and belongs to the technical field of biology. Comprising the following steps: washing and resuspending magnetic nanoparticles; activating the magnetic nanoparticles to obtain activated magnetic nanoparticles; carrying out reaction on polyoxyethylene diamine and the activated magnetic nanoparticles to obtain a polyoxyethylene diamine modified magnetic nanoparticle compound; the preparation method comprises the following steps: reacting glutaraldehyde with a polyoxyethylene diamine modified magnetic nanoparticle compound to obtain a substance A; the method comprises the following steps: reacting cefepime with a substance A to obtain a polyoxyethylene diamine mediated cefepime functionalized magnetic nanoparticle compound; and enriching and capturing. According to the present invention, the polyoxyethylene diamine is adopted as the mediator so as to reduce the steric hindrance, the cefepime is adopted as the recognition element so as to improve the binding force with bacteria, and the nano-scale magnetic beads with the large specific surface area are adopted to improve the loading capacity of the recognition element so as to improve the bacteria capture efficiency. Compared with the traditional method, the method has the advantages of short incubation time, less material consumption, low cost and wide adaptability.

The invention relates to a cefepime hydrochloride medicine composition, a powder-injection thereof and a preparation method thereof. The medicine composition comprises the following ingredients: cefepime hydrochloride, L-arginine and hydroxypropyl-beta-cyclodextrin, wherein the weight of the L-arginine is 40% of that of the cefepime hydrochloride, and the weight of the hydroxypropyl-beta-cyclodextrin is 10% of that of the cefepime hydrochloride. The medicine composition is good in mixing uniformity, has small pH value change in subpackaging and transportation processes, is small in gastrointestinal tract side effect, and greatly improves the stability and safety of the medicine.

The invention relates to a measurement method of N-methylpyrrolidine content of cefepime dihydrochloride material and relative agent, for evaluating the quality of cefepime dihydrochloride material and relative agent. The invention discloses a liquid chromatograph which comprises using carboxylic cationic column as analysis column, uses a conductive detector to check, preparing flow phase, preparing sample solution and reference substance solution, using test method to respectively inject the sample solution and reference substance solution into a liquid chromatograph, recording high pressure liquid chromatographs, and calculating the N-methylpyrrolidine content of the sample. The inventive chromatograph system has easy balance, short sample test time, better repeatability in preserved time, stable baseline, durable column, high quality of chromatograph peak of N-methylpyrrolidine, better repeatability, accurate, simple and reliable process.

The invention discloses a cefepime dihydrochloride compound. The cefepime dihydrochloride compound is prepared by a following method comprising the following steps: (1) dissolving a cefepime dihydrochloride crude product into water and performing membrane separation and impurity removal by selecting a separating membrane with the molecular weight cut off of 500-3000; (2) adding the impurity-removed solution into an organic solvent, then adding active carbon into the obtained solution, stirring, filtering the solution to remove charcoal, and collecting the filter solution; (3) separating and purifying the filter solution with a chromatographic column, wherein a mobile phase is a mixed solvent of isopropanol and acetonitrile, and a stationary phase filler is silica gel or aluminum oxide; and (4) concentrating the separated and purified filter solution, and performing spray-drying to obtain the cefepime dihydrochloride compound. The invention also discloses a pharmaceutical composition containing the cefepime dihydrochloride compound, wherein the pharmaceutical composition is sterile powder for injection. The cefepime dihydrochloride compound and the pharmaceutical composition disclosed by the invention have low impurity content and few toxic and side effects, so that the medication safety of the patient is greatly improved.

The invention discloses an HPLC detection method for high-molecular impurities in cefepime and a preparation thereof. The method comprises the steps of separating and measuring polymer impurities in the cefepime and the preparation thereof by using a high performance liquid chromatograph and an isocratic elution method, wherein a chromatographic column with the detection wavelength of 254 +/-2nm takes globular protein chromatographic hydrophilic silica gel as a filler, and a mixed solution consisting of a phosphate buffer solution with the concentration of 0.005 mol/L and the volume percentage of 87.5 to 92.5% and an organic phase with the volume percentage of 7.5 to 12.5% is used as a mobile phase. According to the method, the quality of the high-molecular impurities in cefepime and the preparation thereof can be controlled, and the product quality and medication safety are guaranteed.

The invention relates to a bangosome retinoic acid aerosol which can prevent chronic obstructive pulmonary. The ingredients of the aerosol include: retinoic acid bangosome, cefepime or ceftazidime, fluormone or cetacort and distilled water. The mentioned retinoic acid bangosome is made of the following materials: 1-2 share (by weight) retinoic acid, 10-15 shares (by weight) cholesterol, 10-15 shares (by weight) lecithin and 0.01-0.2 VE. The producing procedures go as follows: mix 2-3 shares (by weight) retinoic acid bangosome with 0.1-0.2 cefepime or ceftazidime, 0.0005-0.0025 fluormone or 0.01-0.05 cetacort; add distilled water to the ingredients at the ratio of 1:15-1:20; fill the material into clean jars to get the aerosol.

The invention relates to a synthesis method of cefepime hydrochloride, which comprises the following steps: by taking 7-amino-3-chloromethyl-3-cephem-4-carboxylic acid diphenylmethyl ester hydrochloride as a raw material, protecting amino by using di-tert-butyl dicarbonate ester, reacting with N-methylpyrrolidine, and removing 4-site and 7-site protecting groups by using acid to obtain an intermediate 7-amino-3-(1-methyltetrahydropyrrole)methyl)-3-cephem-4-carboxylic acid hydrochloride (7-ACP); and then carrying out an acylation reaction with aminothiazide sulfhydryl benzothiazole active ester (AE-active ester) to obtain the product. The route has the advantages of simple reaction treatment, harsh reaction conditions, less isomer generation, high yield, high purity and simple process, and the method is suitable for industrial production.

Pharmaceutical compositions comprising a beta-lactam compound selected from cefepime, sulbactam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.

The invention discloses an application of pulsatilla saponin A3 in inhibiting the growth of multi-drug-resistant Providencia rettgeri. According to the invention, the pulsatilla saponin A3 has good in-vitro killing effect on human-derived Providencia rettgeriis with resistance to ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, tobramycin, piperacillin tazobactam,ciprofloxacin, levofloxacin, amikacin, compound phenoxymine, cefepime, ertapenem, imipenem, aztreonam and gentamicin, can inhibit in-vitro growth of the multi-drug-resistant Providencia rettgeri, andhas a minimum inhibitory concentration of 125 [mu]g/mL and a minimum bactericidal concentration of 250 [mu]g/mL. The pulsatilla saponin A3 provided by the ivnention has an antibacterial effect on themulti-drug-resistant Providencia rettgeri, can relieve or solve the problem that the drug resistance of the multi-drug-resistant Providencia rettgeri is increased, and provides a theoretical basis forclinical antibacterial treatment and novel drug research and development.

The invention relates to the technical field of medicinal preparation, and discloses cefepime hydrochloride, a preparation, a preparation method and a new indication for treating tympanitis. The cefepime hydrochloride provided by the specific preparation method is low in impurity content, high in stability and remarkable in medicine effect, the quality of a preparation product is improved, the safety and effectiveness of the preparation product are guaranteed, and the cefepime hydrochloride has the application in the aspect of preparing a medicine for treating tympanitis.